FDA approves 23andMe's genetic screening test for rare disorder

February 20, 2015 1:29 AM

15 0

WASHINGTON (Reuters) - Google-backed 23andMe won U.S. approval on Thursday to market the first direct-to-consumer genetic test for a mutation that can cause children to inherit Bloom syndrome, a rare disorder that leads to short height, an increased risk of cancer and unusual facial features.

The Food and Drug Administration said it plans to issue a notice to exempt this and other carrier screening tests from the need to win FDA review before being sold. There will be a 30-day period for public comment.

Read more

To category page